Increased serum levels of soluble CD163 in patients with scleroderma

Shimizu, Kazuhiro; Ogawa, Fumihide; Yoshizaki, Ayumi; Akiyama, Yuichiro; Kuwatsuka, Yutaka; Okazaki, Satoru; Tomita, Hajime; Takenaka, Motoi; Sato, Shinichi

doi:10.1007/s10067-012-1972-x

Cited by 30 publications

(27 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results confirmed the results of others who found an increased serum sCD163 level in patients with SSc compared with that in healthy controls (20)(21)(22).…”

Section: Discussionsupporting

confidence: 92%

“…Shimizu et al (22) suggested that increased sCD163 was attributed to the presence and degree of oxidative stress, and SSc is considered to be one of the oxidative stresses, and they found a positive correlation between sCD163 and serum 8-isoporstane, which is considered to be a marker of lipid peroxidation, in patients with SSc. Furthermore, Guiducci et al (23) suggested that the main function of sCD163 to bind haptoglobin-hemoglobin complexes and to prevent vessel wall injury is beneficial in SSc, as microangiopathy is also present as a prominent feature of SSc and might lead to increased hemolysis and the release of free hemoglobin.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Soluble CD163 and its association with various disease parameters in patients with systemic sclerosis

et al. 2016

View full text Add to dashboard Cite

Objective: Cluster of differentiation 163 (CD163) is a receptor that binds haptoglobin-hemoglobin complexes and is mainly expressed on macrophages and monocytes. As a result of shedding, the extracellular portion of CD163 circulates in the blood as a soluble CD163 (sCD163). This study aimed to measure serum sCD163 levels in patients with systemic sclerosis (SSc) and to assess its association with the clinical, laboratory, and radiological features of the disease. Material and Methods:We measured serum sCD163 levels in 24 patients with SSc and in 30 healthy controls. Complete history of the patients was recorded and thorough clinical, rheumatological, and dermatological examinations were performed. For SSc, the skin thickness score was scored according to the modified Rodnan skin score method and pulmonary involvement was assessed in all patients using high-resolution computed tomography and by performing pulmonary function tests. Results:The mean serum sCD163 levels in patients with diffuse and limited SSc (61.64±19.57 and 60.8±21.43 ng/mL, respectively) demonstrated a highly statistically significant increase compared with the mean serum levels in healthy controls (36.97±16.37 ng/ mL) (p<0.001). Patients with SSc having elevated serum sCD163 levels had significantly higher pulmonary artery systolic pressure (PASP) than those with normal serum sCD163 levels (p<0.05). Furthermore, the serum sCD163 levels were significantly correlated with PASP (r=0.53, p<0.05) in patients with SSc. The mean serum sCD163 level in patients with SSc having digital ulceration (DU) (70.82±18.3 ng/mL) demonstrated a statistically significant increase (p<0.05) compared with that in SSC patients without DU (53.23±18.09 ng/mL). Conclusion:The elevated serum sCD163 levels in patients with SSc and its association with pulmonary hypertension suggest a possible role of macrophages in the pathogenesis and vascular involvement of SSc.

show abstract

“…Our results confirmed the results of others who found an increased serum sCD163 level in patients with SSc compared with that in healthy controls (20)(21)(22).…”

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Serum Soluble CD163 and its association with various disease parameters in patients with systemic sclerosis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…and Shimizu et al . In those two studies, which included 43 and 56 Japanese patients with SSc, respectively, serum concentration of sCD163 was significantly higher in scleroderma patients compared with the control group [23,24]. We have confirmed those observations in a greater population derived from several clinical centres.…”

Section: Discussionsupporting

confidence: 81%

“…Of note, was that previous studies had found an association between high serum sCD163 levels and greater frequency of PH or higher pulsatility index, which is a surrogate marker of kidney arterial injury [23,24]. However, neither of these two previous reports separately evaluated relationships between serum sCD163 levels and active DU [23,24].…”

Section: Discussionmentioning

confidence: 99%

High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis

et al. 2013

View full text Add to dashboard Cite

IntroductionSystemic sclerosis (SSc) is an autoimmune disease characterized by chronic inflammation, vascular injury and excessive fibrosis. CD163 is a scavenger receptor which affects inflammatory response and may contribute to connective tissue remodelling. It has recently been demonstrated that CD163 can bind and neutralize the TNF-like weak inducer of apoptosis (TWEAK), a multifunctional cytokine which regulates inflammation, angiogenesis and tissue remodelling. We aimed to investigate the relationships between serum levels of soluble CD163 (sCD163) and soluble TWEAK (sTWEAK) in relation to disease manifestations in SSc patients.MethodsThis study included 89 patients with SSc who had not received immunosuppressive drugs or steroids for at least 6 months and 48 age- and sex-matched healthy controls (HC) from four European centres. Serum concentrations of sTWEAK and sCD163 were measured using commercially available ELISA kits.ResultsThe mean serum concentrations of sTWEAK were comparable between SSc patients (mean +/- SD: 270 +/- 171 pg/mL) and HC (294 +/- 147pg/mL, P >0.05). Concentration of sCD163 and sCD163/sTWEAK ratio were significantly greater in SSc patients (984 +/- 420 ng/mL and 4837 +/- 3103, respectively) as compared to HC (823 +/- 331 ng/mL and 3115 +/- 1346 respectively, P <0.05 for both). High sCD163 levels and a high sCD163/sTWEAK ratio (defined as > mean +2SD of HC) were both associated with a lower risk of digital ulcers in SSc patients (OR, 95%CI: 0.09; 0.01, 0.71, and 0.17; 0.06, 0.51, respectively). Accordingly, patients without digital ulcers had a significantly higher sCD163 concentration and sCD163/sTWEAK ratio as compared to SSc patients with digital ulcers (P <0.01 for both) and HC (P <0.05 for both). A high sCD163/sTWEAK ratio, but not high sCD163 levels, was associated with greater skin involvement.ConclusionsThe results of our study indicate that CD163-TWEAK interactions might play a role in the pathogenesis of SSc and that CD163 may protect against the development of digital ulcers in SSc. Further studies are required to reveal whether targeting of the CD163-TWEAK pathway might be a potential strategy for treating vascular disease and/or skin fibrosis in SSc.

show abstract

“…Cutaneous macrophage infiltration has been suggested to be associated with refractory aGVHD and poor prognosis (16). Alternatively, activated macrophages (CD163 + ) have been previously shown to be present in both humans (17) and rats with systemic sclerosis (18). Additionally, macrophages displaying an M2 phenotype are present in the skin (19) and lungs of patients with systemic sclerosis (20).…”

Section: Introductionmentioning

confidence: 99%

CSF-1–dependant donor-derived macrophages mediate chronic graft-versus-host disease

Alexander¹,

Flynn²,

Lineburg³

et al. 2014

J. Clin. Invest.

191

170

View full text Add to dashboard Cite

Increased serum levels of soluble CD163 in patients with scleroderma

Cited by 30 publications

References 31 publications

Serum Soluble CD163 and its association with various disease parameters in patients with systemic sclerosis

Serum Soluble CD163 and its association with various disease parameters in patients with systemic sclerosis

High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis

CSF-1–dependant donor-derived macrophages mediate chronic graft-versus-host disease

Contact Info

Product

Resources

About